April 2, 2025

Elizabeth Mauro
Director, Global Regulatory Science
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001
Re: Revocation of EUA202920

Dear Elizabeth Mauro:
This letter is in response to the request from Pfizer Inc., in letter dated March 14, 2025, that the U.S. Food and Drug Administration (FDA) revoke the EUA for the Lucira COVID-19 All-In-One Test Kit issued on November 17, 2020, amended on September 23, 2021, and July 28, 2022, and revised and reissued on November 15, 2022, and June 14, 2023. Pfizer Inc. indicated that they did not distribute the authorized product and requested that the EUA be revoked. FDA understands that as of the date of this letter there are no viable Lucira COVID-19 All-In-One Test Kit reagents in distribution in the United States.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because Pfizer Inc. has requested that FDA revoke the EUA for the Lucira COVID-19 All-In-One Test Kit, FDA has determined that it is appropriate to protect the public health or safety to revoke this authorization. Accordingly, FDA hereby revokes EUA202920 for the Lucira COVID-19 All-In-One Test Kit, pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the Lucira COVID-19 All-In-One Test Kit is no longer authorized for emergency use by FDA.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act.

Sincerely,

_____
Ellen J. Flannery, J.D.
Deputy Center Director for Policy
Director, Office of Policy
Center for Devices and Radiological Health
Food and Drug Administration